Cancer News and Research

Latest Cancer News and Research

Galectin-1 drives growth of Kaposi sarcoma tumors

A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.

2 Oct 2012

BHGI sponsors global summit on international breast health

For women with breast cancer in low- and middle-resource countries and other medically underserved areas around the world, the need for supportive care and the consideration of quality-of-life issues are often overlooked.

2 Oct 2012

Zinc deficiency mechanism associated with many health problems, aging

A new study has outlined for the first time a biological mechanism by which zinc deficiency can develop with age, leading to a decline of the immune system and increased inflammation associated with many health problems, including cancer, heart disease, autoimmune disease and diabetes.

2 Oct 2012

Proton pump inhibitors does not lead to higher rates of pneumonia

Previous studies that have associated the use of proton pump inhibitors (PPI) - which include popular anti-heartburn medications like Prilosec and Nexium - with an increased incidence of pneumonia may not have found a true cause-and-effect relationship.

2 Oct 2012

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.

2 Oct 2012

F-18-FLT-PET predicts early response to chemoradiotherapy in head and neck cancer

Determining the optimal treatment course and predicting outcomes may get easier in the future for patients with head and neck sqaumous cell carcinomas (HNSCCs) with the use of an investigational imaging agent.

2 Oct 2012

Loyola launches experimental immune system therapy clinical trial for melanoma in the Midwest

Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient's immune system to fight the deadly cancer.

2 Oct 2012

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA.

2 Oct 2012

GnRH agonist may protect breast cancer patient fertility

Treatment with a gonadotropin-releasing hormone agonist may reduce the risk for chemotherapy-induced amenorrhea, research shows.

1 Oct 2012

Incidence of esophageal, stomach cancers increased in AIDS

The risk for esophageal and stomach carcinomas, as well as non-Hodgkin lymphomas, is significantly increased in people with AIDS, although the incidence of lymphomas has decreased, the results of a US and UK study reveal.

1 Oct 2012

Genetic profile predicts postradiation erectile dysfunction

Scientists have identified a group of genetic markers that can predict the risk for erectile dysfunction after radiotherapy for prostate cancer.

1 Oct 2012

Autoimmune disease myasthenia gravis halted in mice

Working with mice, Johns Hopkins researchers say they have developed a gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis by specifically targeting the destructive immune response the disorder triggers in the body.

1 Oct 2012

Participatory pay-for-performance improves primary care

Both quality of care measures and patient experience may be achieved through the introduction of a participatory pay-for-performance program, study findings indicate.

1 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.

1 Oct 2012

Five prominent surgeons receive Honorary Fellowship from ACS

Last night Honorary Fellowship in the American College of Surgeons (ACS) was awarded to five prominent surgeons from Japan, the Philippines, Mexico, England, and Belgium during Convocation ceremonies that preceded the official opening of the 2012 ACS Annual Clinical Congress.

1 Oct 2012

Medistem initiates collaboration with Superview Biotechnology

Medistem Inc announced today the initiation of a collaboration with Superview Biotechnology Co. Ltd, a subsidiary of Yinhuan Holding Co from Yixing, China.

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Study opens new door to more personalized treatment of advanced breast cancer

For the first time, researchers have conducted a large trial in which they tested the entire genome of individual breast cancers to help personalize treatment. They released their findings at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Inhibiting DUSP6 protein can restore immune cells’ responsiveness to a more youthful state

The older we get, the weaker our immune systems tend to become, leaving us vulnerable to infectious diseases and cancer and eroding our ability to benefit from vaccination. Now Stanford University School of Medicine scientists have found that blocking the action of a single protein whose levels in our immune cells creep steadily upward with age can restore those cells' response to a vaccine.

1 Oct 2012

Cancer News and Research

Latest Cancer News and Research

Galectin-1 drives growth of Kaposi sarcoma tumors

BHGI sponsors global summit on international breast health

Zinc deficiency mechanism associated with many health problems, aging

Proton pump inhibitors does not lead to higher rates of pneumonia

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

F-18-FLT-PET predicts early response to chemoradiotherapy in head and neck cancer

Loyola launches experimental immune system therapy clinical trial for melanoma in the Midwest

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

GnRH agonist may protect breast cancer patient fertility

Incidence of esophageal, stomach cancers increased in AIDS

Genetic profile predicts postradiation erectile dysfunction

Autoimmune disease myasthenia gravis halted in mice

Participatory pay-for-performance improves primary care

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

Five prominent surgeons receive Honorary Fellowship from ACS

Medistem initiates collaboration with Superview Biotechnology

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Study opens new door to more personalized treatment of advanced breast cancer

Inhibiting DUSP6 protein can restore immune cells’ responsiveness to a more youthful state

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in